Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

Parkinson’s Disease is a progressive neurological disorder that will eventually lead to a late or end‑stage with severe symptoms and complex care requirements. The phase needs to be addressed for ...

Add Yahoo as a preferred source to see more of our stories on Google. Scientists, using artificial intelligence (AI), have linked these bacterial changes to cognitive decline – which includes memory ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

In its early stages, Parkinson's disease is not easy to diagnose. But a new test that's been in development for a decade could change how we look at the disease.

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...

Parkinson’s Cafe@AH allows multidisciplinary teams to monitor patients in a relaxed environment. Read more at straitstimes.com. Read more at straitstimes.com.

(RTTNews) - Ventyx Biosciences, Inc. (VTYX) announced Tuesday positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage ...

This week, Bobbi Conner talks with MUSC's Dr. Vanessa Hinson about research underway to explore the use of stem cell therapy ...

Changes in the bacteria found in the mouth and gut of Parkinson’s disease patients could act as an early warning sign that their symptoms are worsening, new research suggests. Scientists, using ...